Navigation Links
Pharmsynthez Reports Full Year 2012 Results in line US GAAP Financial Reporting
Date:7/17/2013

ST. PETERSBURG, Russia, July 17, 2013 /PRNewswire/ --

OJSC Pharmsynthez (Leningrad region, MICEX: LIFE) ("Pharmsynthez" or "the Company"), the leading Russian biopharmaceutical company that specializes in the development, manufacture and distribution of pharmaceuticals, has today published its consolidated audited results for the full year period ending 31 December 2012, in line with US GAAP. The results were compiled by leading global auditor, Ernst & Young.

Highlights

  • Consolidated sales of $8.5million (2011: $6.7 mln.)
  • Revenue of $12.7million in 2012 inclusive of Government co-financing of R&D
  • Consolidated gross profit $4.7million (2011: $3.7million)
  • Stable gross margin at 55%
  • EBITDA loss of $0.4million (2011: $0.4million) due to the strategic goal to increase R&D expenditures, exceeding the amount of Government co-financing
  • Virexxa Phase II clinical trial planned to begin in the US and EU in the third quarter of 2013
  • Myeloxen Phase IIa clinical research ongoing with results expected in the fourth quarter
  • Pulmoxen Phase I trial to begin during the third quarter

Dmitry Genkin, Chairman of Pharmsynthez, commented, "These positive operating indicators, including the growth in revenue, were achieved mainly thanks to the successive realization of plans to expand into the pharmaceutical markets of the Former Soviet Union and wider international markets. This has been key strategic objective of the Board and we are confident this will help deliver further growth and value for shareholders."

Notes to Editors

Pharmsynthez is a leading Russian pharmaceutical company focused on research, manufacture and distribution of active pharmaceutical ingredients (APIs), including those intended for import substitution.  Pharmsynthez also produces me
'/>"/>

SOURCE Pharmsynthez
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Avizia, Inc., a leading provider of cutting-edge ... equity financing round led by NextGen Angels along with ... will be used to continue to fuel the rapidly ... Edward Kennedy , CEO and president of Tollgrade ... Leonard Kurtzman , CFO of newBrandAnalytics, who joined the ...
(Date:8/19/2014)... MALVERN, Pa. , Aug. 19, 2014  SCILEX ... commercialization of late-stage pharmaceutical products for the treatment of ... composed of four members: Dr. Jeff Gudin , ... and Mr. Kip Vought . ... said the expertise of this board would greatly assist ...
(Date:8/19/2014)... Aug. 19, 2014 Luoxis Diagnostics, ... Inc. (NYSE MKT: AMPE), today announced an ... Meeting of the American Academy of Surgical Trauma ... in Philadelphia, Pennsylvania that ... will report results from a recently completed five-year ...
Breaking Medicine Technology:Avizia Closes Funding Round 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... Calif., Dec. 21 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI ) ... Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation ... a successful Phase 2 program in patients with advanced prostate ...
... , SAN DIEGO, Dec. 18 LifeVantage Corporation ... Anti-Aging Cream, science-based solutions to oxidative stress, announced today that ... other parties, Zrii, LLC. Under the terms of this agreement, ... William Farley, on the one hand, and the Company and ...
Cached Medicine Technology:Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3LifeVantage Announces Settlement of Zrii Litigation 2LifeVantage Announces Settlement of Zrii Litigation 3
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... specialization and a low availability of substitutes typify the ... buyer power score of 3.1 out of 5, indicating ... buyer power suggests buyers and suppliers have an equal ... research analyst Kayley Freshman-Caffrey. , First, few substitutes exist ...
(Date:8/20/2014)... August 20, 2014 First Choice ... emergency rooms in the United States, named Richard Daniels, ... FM 685 facility. , “We are pleased to ... director of our second facility in Pflugerville,” said Dr. ... Emergency Room. , Dr. Daniels received his undergraduate ...
(Date:8/20/2014)... 20, 2014 Kowa Optimed returns after ... to debut the new SL-17 portable slit lamp. , ... white LED source controlled by an illuminated thumb wheel ... SL-17 uses commercially available AAA rechargeable and dry cell ... design requiring batteries designed specifically for the device. The ...
(Date:8/20/2014)... August 20, 2014 This agreement ... of software defined networking, high availability cloud enablement, ... of Resellers, while allowing OPEN-V to sell storageFOUNDRY’s ... pleased to work with OPEN-V on this distribution ... Hows, manager distribution channels at storageFOUNDRY. "Nautilus is ...
(Date:8/19/2014)... 2014 Midtown Dentistry in Houston, Texas, is ... All patients with cavities, or with old fillings that ... that can safely repair and restore teeth. , From now ... materials, all of which are completely amalgam free. Even though ... by the FDA for adults and children over the age ...
Breaking Medicine News(10 mins):Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... Health System set out to reduce energy consumption, they weren,t ... at healthcare facilities. Instead, they,re aiming for a 20 percent ... metric tons of carbon dioxide annually that,s not being released ... the road. The La Crosse, Wis.-based health system is on ...
... a statement by UNITE HERE General President Bruce Raynor:Contrary ... press contact, today,s General Executive Board meeting ended with ... President of UNITE HERE. To be crystal clear: I ... authorized Wilhelm to discuss this issue with me.(Logo: ...
... Only two percent of hospitals nationwide receive Magnet ... Center (ANCC) has announced that Baylor University ... earned re-designation as a Magnet hospital, effective immediately. ... been designated at a Magnet hospital, and merely ...
... Pharmos Corporation (Pink Sheets: PARS) announced today that ... and warrants. At the closing, the Company issued ... an additional 18,000,000 shares of common stock for an ... of the warrants, which have a five-year term, is ...
... 2009 (BRONX, NY) Recurrent and metastatic endometrial ... They have spread to other organs and typically have ... with chemotherapy may not be able to endure more ... of Yeshiva University have shown that a combination of ...
... Exposition Park LOS ANGELES, ... of Dimes premier fundraising event that benefits all babies--those born ... 11,000 walkers are expected at this largest March for Babies ... Park, at the corner of S. Figueroa and 39th St., ...
Cached Medicine News:Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Statement From UNITE HERE General President Bruce Raynor on Today's General Executive Board Meeting 2Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 3Health News:New treatment shows promise against recurrent gynecologic cancers 2Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2
IBT Reference Laboratory is a national research and specialty clinical lab founded in 1983 that provides a wide range of tests and services in the area of allergy, clinical immunology and molecular b...
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
Medicine Products: